Triple therapy-based targeted nanoparticles for the treatment of Helicobacter pylori

Journal of Drug Targeting

Volumn 16, Issue 9, 2008, Pages 694-705

  Ramteke, Suman ^a   Ganesh, N ^b   Bhattacharya, S ^c   Jain, Narendra ^d  

^a UNIVERSITY INSTITUTE OF TECHNOLOGY   (India)

^b Jawaharlal Nehru Cancer Hospital & Research Centre Bhopal   (India)

^c BIRLA INSTITUTE OF TECHNOLOGY   (India)

^d DR H S GOUR UNIVERSITY   (India)

Author keywords

Amoxicillin; Clarithromycin; Gliadin; Mucoadhesion; Nanoparticles; Omeprazole; Triple therapy

Indexed keywords

1 (3 DIMETHYLAMINOPROPYL) 3 ETHYLCARBODIIMIDE; 6 CARBOXYFLUORESCEIN; AMOXICILLIN; CLARITHROMYCIN; GLIADIN; LECTIN; NANOPARTICLE; OMEPRAZOLE; PLACEBO; POLOXAMER;

AGGLUTINATION TEST; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG POTENTIATION; DRUG RELEASE; DRUG SELECTIVITY; DRUG TARGETING; ERADICATION THERAPY; FEMALE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HISTOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NEWBORN; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; TREATMENT OUTCOME; ZETA POTENTIAL;

AMOXICILLIN; ANIMALS; ANTI-BACTERIAL AGENTS; ANTI-ULCER AGENTS; CLARITHROMYCIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; FEMALE; GLIADIN; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; LECTINS; MALE; MICE; NANOPARTICLES; OMEPRAZOLE; TIME FACTORS;

EID: 55849121922     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.1080/10611860802295839     Document Type: Article

References (44)

1. Arangoa, MA, Ponchel, G., Orecchioni, AM, Renedoi, MJ, Duchene, D. and Irache, JM (2000) Bioadhesive potential of gliadin nanoparticles systems. Eur J Pharm Sci, 11, pp. 333-341.
2. Ascencio, F., Guruge, JL, Ljungh, A., Megraud, F., Wei, S. and Wadstrm, T. (1990) Lectin typing of Helicobacter pylori. Helicobacter pylori, gastritis and peptic ulcer, pp. 105-109. Springer-Verlag, Berlin
3. Bardhan, KD, Dallaire, C., Eisold, H. and Duggan, AE (1997) Ranitidine bismuth citrate with clarithromycin for the treatment of duodenal ulcer. Gut, 41, pp. 181-186.
4. Benaissa, M., Babin, P., Quellard, N., Pezennec, L., Cenatiempo, A. and Fauchere, JL (1996) Changes in Helicobacter pylori ultrastructure and antigens during conversion from the bacillary to the coccoid from. Infect Immun, 64, pp. 2331-2335.
5. Chiba, N., Rao, BV, Rademaker, JW and Hunt, RH (1992) Meta-analysis of the efficacy of antibiotic therapy in eradicating Helicobacter pylori. Am J Gastroenterol, 87, pp. 1716-1727.
6. Copland, MJ, Baird, MA, Rades, T., McKenzie, JL, Becker, B., Reck, F., Tyler, PC and Davies, NM (2003) Liposomal delivery of antigen to human dendritic cells. Vaccine, 21, pp. 883-890.
7. Doglioni, C., Wotherspoon, AC, Moschini, A., De Boni, M. and Isaacson, PG (1992) High incidence of primary gastric lymphoma in northeastern Italy. Lancet, 339, pp. 834-835.
8. Dunn, BE (1993) Pathogenic mechanisms of Helicobacter pylori. Gastroenterol Clin North Am, 22, pp. 43-57.
9. Durrer, C., Irache, JM, Puisieux, F., Duchene, D. and Ponchel, G. (1994) Mucoadhesion of latexes. II. Adsorption isotherms and desorption studies. Pharm Res, 11, pp. 680-683.
10. Forman, D., Newell, DG, Fullerton, F., Yarnell, JW, Stacey, AR, Wald, N. and Sitas, F. (1991) Association between infection with Helicobacter pylori and risk of gastric cancer: Evidence from a prospective investigation. BMJ, 302, pp. 1302-1305.
11. Goodwin, CS (1994) Haemagglutinins of Helicobacter pylori and adherence to Hep-2 cells. Basic and clinical aspects of Helicobacter pylori infection, pp. 90-91. Springer Verlag, Berlin, Heidelberg
12. Gupta, PK, Leung, SH and Robinson, JR (1990) Bioadhesive drug delivery systems, 65, p. 92. CRC Press, Boca Raton, FL
13. Gustavson, LE, Kaiser, JF, Edmond, AL, Locke, CS, DeBartolo, MI and Schneck, DW (1995) Effect of omeprazole on concentration of clarithromycin in plasma and gastric tissue at study state. Antimicrob Agents Chemother, 39:9, pp. 2078-2083.
14. Irache, JM, Durrer, C., Duchene, D. and Ponchel, G. (1994) Preparation and characterization of lectin-latex conjugates for specific bioadhession. Biomaterials, 15, pp. 899-904.
15. Ishak, RAH, Awad, GAS, Mortada, ND and Nour, SAK (2007) Preparation, in vitro and in vivo evaluation of stomach specific metronidazole loaded alginate beads as local anti-Helicobacter pylori therapy. J Control Release, 119, pp. 207-214.
16. Kate, V. and Ananthakrishnan, N. (2001) Treatment of Helicobacter pylori infection-A review. Indian J Pharmcol, 33, pp. 410-416.
17. Kawashima, Y., Yamamoto, H., Takeuchi, H. and Kuno, Y. (2000) Mucoadhesive, D,L-lactide/glycolide copolymer nanospheres coated with chitosan to improve oral delivery of elcatonin. Pharm Dev Technol, 5, pp. 77-85.
18. Kulkarni, SK and Gupta, M. (1999) Current concepts and drug therapy of Helicobacter pylori infection. Indian J Pharm Sci, 61:6, pp. 323-334.
19. Marshall, BJ (1991) Virulence and pathogenicity of Helicobacter pylori. J Gastroenterol Hepatol, 6, pp. 121-124.
20. Marshall, BJ and Warren, JR (1984) Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet, pp. 1311-1315.
21. Moss, S. and Calam, J. (1992) Helicobacter pylori and peptic ulcers: The present position. Gut, 33, pp. 289-292.
22. Nagagara, N., Akiyama, Y., Nakao, M., Tada, M., Kitano, M. and Ogawa, Y. (1998) Mucoadhessive microspheres containing amoxicillin for clearance of Helicobacter pylori. Antimicrob Agents Chemother, 42, pp. 2492-2494.
23. O'Sullivan, N., Benjamin, J. and Skirrow, MB (1990) Lectin typing of Campylobacter isolates. J Clin Pathol, 43, pp. 957-960.
24. Olde Damink, LH, Dijkstra, PJ, van Luyn, MJ, van Wachem, PB, Nieuwenhuis, P. and Feijen, J. (1996) In vitro degradation of dermal sheep cpllegen cross-linked using a water soluble carbodiimide. Biomaterials, 17, pp. 679-684.
25. Peitz, U., Sulliga, M., Wolle, K., Leodolter, A., von Arnim, U. Kahl, S. et al. (2002) High rate of post-therapeutic resistance after failure of macrolide nitromidazole triple therapy to cure Helicobacter pylori infection: Impact of two second-line therapies in a randomized study. Aliment Pharmacol Ther, 16, pp. 315-324.
26. Peppas, NA and Huang, Y. (2004) Nanoscale technology of mucoadhessive interaction. Adv Drug Deliv Rev, 56, pp. 1675-1687.
27. Peterson, WL, Graham, DY, Marshall, B., Blaser, MJ, Genta, RM Klein, PD et al. (1993) Clarithromycin as monotherapy for eradication of Helicobacter pylori: A randomized, double blind trial. Am J Gastroenterol, 88, pp. 1860-1864.
28. Prausnitz, MR, Lau, BS, Milano, CD, Conner, S., Langer, R. and Weaver, JC (1993) A quantitative study of electroporation showing a plateau in net molecular transport. Biophys J, 65, pp. 414-422.
29. Rajotte, D., Arap, W., Hagedorn, M., Koivunen, E., Pasqualini, R. and Ruoslahti, E. (1998) Molecular heterogeneity of the vascular endothelium revealed by in vivo phage display. J Clin Invest, 102, pp. 430-437.
30. Ramteke, S. and Jain, NK (2008) Clarithromycin and omeprazole containing gliadin nanoparticles for the treatment of Helicobacter pylori. J Drug Target, 16:1, pp. 65-72.
31. Ramteke, S., Umamaheshwari, RB and Jain, NK (2006) Clarithromycin based oral sustained release nanoparticulate drug delivery system. Indian J Pharm Sci, 68:4, pp. 479-484.
32. Sharon, N. and Lis, H. (1972) Lectins. Cell agglutinating and sugar specific proteins. Science, 177, pp. 949-959.
33. Sjostrom, JE, Fryklund, J., Kuhler, T. and Larsson, H. (1996) In vitro antibacterial activity of omeprazole and its selectivity for Helicobacter spp. are dependent on incubation conditions. J Med Microbiol, 44, pp. 425-433.
34. Taylor, DN and Blaser, MJ (1991) The epidemiology of Helicobacter pylori infection. Epidemiol Rev, 13, pp. 42-59.
35. Umamaheshwari, RB and Jain, NK (2003) Receptor mediated targeting of lectin conjugated gliadin nanoparticles in the treatment of Helicobacter pylori. J Drug Target, 11:7, pp. 415-424.
36. Umamaheshwari, RB, Jain, P. and Jain, NK (2003) Site-specific drug delivery of acetohydroxamic acid for the treatment of H. pylori. STP Pharm Sci, 13:1, pp. 41-48.
37. Umamaheshwari, RB, Jain, S., Bhadra, D. and Jain, NK (2003) Floating microspheres bearing acetohydroxamic acid for the treatment of Helicobacter pylori. J Pharm Pharmacol, 55, pp. 1607-1613.
38. Umamaheshwari, RB, Jain, S. and Jain, NK (2003) A new approach in gastroretentive drug delivery system using Cholestyramine. Drug Deliv, 10, pp. 151-160.
39. Umamaheshwari, RB, Ramteke, S. and Jain, NK (2004) Anti Helicobacter pylori effect of mucoadhesive nanoparticles bearing amoxicillin in experimental gabrils model. AAPS Pharm Sci Tech, 5:2, pp. 1-9.
40. Vasir, JK, Reddy, MK and Labhasetwar, VD (2005) Nanosystems in drug targeting: Opportunities and challenges. Curr Nanosci, 1, pp. 47-64.
41. Wang, J., Tabata, Y., Bi, D. and Morimoto, K. (2001) Evaluation of gastric mucoadhessive properties of aminated gelatin microspheres. J Control Release, 73, pp. 223-231.
42. Wong, KH, Skelton, SK and Feeley, JC (1986) Strain characterization and grouping of Campylobacter jejuni and Campylobacter coli by interaction with lectins. J Clin Microbiol, 23, pp. 407-410.
43. Wotherspoon, AC, Ortiz-Hidalgo, C., Falzon, MR and Isaacson, PG (1991) Helicobacter pylori associated gastritis and primary B-cell lymphoma. Lancet, 338, pp. 1175-1176.
44. Yokel, RA, Dickey, KM and Goldberg, AH (1995) Selective adherence of a sucralfate-tetracycline complex to gastric ulcers: Implications for the treatment of Helicobacter pylori. Biopharm Drug Dispos, 16, pp. 475-479.